학술논문
Amantadine use in the French prospective NS-Park cohort
Document Type
Original Paper
Author
Fabbri, Margherita; Rousseau, Vanessa; Corvol, Jean-Christophe; Sommet, Agnès; Tubach, Florence; De Rycke, Yann; Bertille, Nathalie; Selvarasa, Yajiththa; Carvalho, Stephanie; Chaigneau, Véronique; Brefel-Courbon, Christine; Ory-Magne, Fabienne; Tessier, Samuel; Tir, Melissa; Bereau, Matthieu; Meissner, Wassilios G.; Thiriez, Claire; Marques, Ana; Remy, Philippe; Schneider, Vincent; Moro, Elena; Defebvre, Luc; Houeto, Jean Luc; Prange, Stephane; Eusebio, Alexandre; Geny, Christian; Frismand, Solène; Damier, Philippe; Reuther, Caroline Giordana; Castelnovo, Giovanni; Benatru, Isabelle; De Maindreville, Anne Doe; Drapier, Sophie; Maltête, David; Lagha-Boukbiza, Ouhaid; Rascol, Olivier
Source
Journal of Neural Transmission: Translational Neuroscience, Neurology and Preclinical Neurological Studies, Psychiatry and Preclinical Psychiatric Studies. 131(7):799-811
Subject
Language
English
ISSN
0300-9564
1435-1463
1435-1463
Abstract
Objective: To assess amantadine use and associated factors in the patients with Parkinson’s disease (PD).Background: Immediate-release amantadine is approved for the treatment of PD and is largely used in clinical practice to treat “levodopa-induced dyskinesia (LIDs). Its use varies according to countries and PD stages. The prospective NS-Park cohort collects features of PD patients followed by 26 French PD Expert Centres.Methods: Variables used for the analyses included demographics, motor and non-motor PD symptoms and motor complications [motor fluctuations (MFs), LIDs)], antiparkinsonian pharmacological classes and levodopa equivalent daily dose (LEDD). We evaluated: (i) prevalence of amantadine use and compared clinical features of amantadine users vs. non-users (cross-sectional analysis); (ii) factors associated with amantadine initiation (longitudinal analysis); (iii) amantadine effect on LIDs, MFs, apathy, impulse control disorders and freezing of gait (Fog) (longitudinal analysis).Results: Amantadine use prevalence was 12.6% (1,585/12,542, median dose = 200 mg). Amantadine users were significantly younger, with longer and more severe PD symptoms, greater LEDD and more frequent use of device-aided/surgical treatment. Factors independently associated with amantadine initiation were younger age, longer PD duration, more frequent LIDs, MFs and FoG, higher LEDD and better cognitive function. 9 of the 658 patients on amantadine had stopped it at the following visit, after 12–18 months (1.3%). New users of amantadine presented a higher improvement in LIDs and MF compared to amantadine never users.Conclusions: About 12% of PD patients within the French NS-Park cohort used amantadine, mostly those with younger age and more severe PD. Amantadine initiation was associated with a subsequent reduction in LIDs and MFs.